Mizuho lowered the firm’s price target on Nkarta (NKTX) to $14 from $16 and keeps an Outperform rating on the shares. The firm updated the company’s model post the Q1 report. It moderated the near-term ramp and unadjusted peak sales for NKX019, citing the current competitive landscape in autoimmune diseases.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NKTX:
- Lyell Immunopharma appoints David Shook as CMO, Mark Meltz as general counsel
- Nkarta Announces Leadership Change with New CMO
- Nkarta appoints Shawn Rose as CMO, head of R&D
- Nkarta’s Strategic Enhancements in NKX019 Program and Trial Expansion Drive Positive Buy Rating
- Nkarta, Inc. Reports Q1 2025 Financial Results